SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Syncom Formulations (India) submits newspaper advertisement

17 Aug 2021 Evaluate

Pursuant to Regulation 30 read with Schedule III Part A(A) and in compliance of Regulation 47(l)(b) of SEBI (LODR) Regulations, 2015, Syncom Formulations (India) has informed regarding extract of Standalone Un-Audited Quarterly Financial Results for the Quarter ended 30th June, 2021 was approved in 02/2021-22 Meeting of Board of Directors held on Saturday, 14th August, 2021 at 2.00 pm at the Corporate Office of the company at 207, Saket Nagar, Indore (M.P) 452018. The company has enclosed the newspaper advertisement published on 15/08/2021 in Free Press Journal English edition and Marathi (vernacular) Newspaper.

The above information is a part of company’s filings submitted to BSE.



Syncom Formulations Share Price

14.18 0.17 (1.21%)
10-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1935.25
Dr. Reddys Labs. 1245.50
Cipla 1438.75
Zydus Lifesciences 1150.50
Lupin 2496.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: